ArticleDermatology online journal2026
Café-au-lait macules in a cohort of Greek children genetically diagnosed with neurofibromatosis type 1: Prognostic significance beyond their diagnostic relevance.
Article in Dermatology online journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Café-au-lait macules (CALMs) are often the earliest visible sign of neurofibromatosis type 1 (NF1), a genetic disorder with marked clinical variability. Early characterization of CALM patterns may aid in anticipating systemic disease burden. Objective: To analyze the early appearance, anatomical distribution, and number of CALMs in children with genetically confirmed NF1 and explore associations with central nervous system (CNS) and skeletal manifestations. Methods: We retrospectively reviewed children with genetically confirmed NF1 at a tertiary pediatric hospital in Athens, Greece (2018-2023). Demographic data, CALM count and distribution, mutation type, and systemic involvement were recorded. CALMs were documented through standardized dermatologic assessment and clinical photography. Statistical correlations were evaluated using nonparametric tests. Results: Sixty-three children (33 males, 30 females; mean age 7.5 ± 4.6 years) were included. All had more than 6 CALMs (mean 18.1 per child), most frequently on the thoracic region (53.6%). In 38.1% of patients, more than 6 CALMs were present by 6 months; among those with 6 or fewer at 6 months, 94.9% exceeded this threshold by 24 months. Children with 7-12 CALMs at 12 months had significantly higher frequencies of CNS and skeletal manifestations ( Conclusion: CALMs were predominantly thoracic and showed the steepest increase between 6 and 12 months. Children with 7-12 CALMs at 12 months had greater systemic involvement, supporting early, risk-adapted surveillance strategies in pediatric NF1.
Indexed as
Identifiers
42522512What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.